Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.

Vilsbøll T, Lindahl CØ, Nielsen NF, Tikkanen CK

Diabetes, obesity & metabolism9 Mar 2023Cited by 20 (Europe PMC)

PMID36809678DOI10.1111/dom.15031PepBankPUB-36809678

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In GLP-1RA-naive people with type 2 diabetes, HbA1c fell by 12.6 mmol/mol after 720 days of once-weekly semaglutide.
In plain wordsIn people with type 2 diabetes new to GLP-1 drugs, HbA1c fell by 12.6 mmol/mol after 2 years of weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change after 720 days, GLP-1RA-naive people
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 720 daysAs given in this study (human).
Measurements
HbA1c change
−12.6 mmol/mol
GLP-1RA-naive, 720 days
Source sentences
Summary
The mean (95% confidence interval) changes in HbA1c after 720 days were -12.6 (-13.6; -11.6) mmol/mol (P < 0.001) for GLP-1RA-naïve people, and -5.6 (-6.2; -5.0) mmol/mol (P < 0.001) for GLP-1RA-experienced people.
1 context sentence(design, population, supporting numbers)
Summary · context
People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included.
Report a problemFND-3680967801
02HumanObservational studyEfficacy outcome
In GLP-1RA-experienced people with type 2 diabetes, HbA1c fell by 5.6 mmol/mol after 720 days of once-weekly semaglutide.
In plain wordsIn people with type 2 diabetes who had used GLP-1 drugs before, HbA1c fell by 5.6 mmol/mol after 2 years of weekly semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change after 720 days, GLP-1RA-experienced people
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 720 daysAs given in this study (human).
Measurements
HbA1c change
−5.6 mmol/mol
GLP-1RA-experienced, 720 days
Source sentences
Summary
The mean (95% confidence interval) changes in HbA1c after 720 days were -12.6 (-13.6; -11.6) mmol/mol (P < 0.001) for GLP-1RA-naïve people, and -5.6 (-6.2; -5.0) mmol/mol (P < 0.001) for GLP-1RA-experienced people.
1 context sentence(design, population, supporting numbers)
Summary · context
People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included.
Report a problemFND-3680967802
03HumanObservational studyEfficacy outcome
In GLP-1RA-naive people with type 2 diabetes, 55% reached an HbA1c target of 53 mmol/mol or lower after 2 years of once-weekly semaglutide.
In plain wordsIn people with type 2 diabetes new to GLP-1 drugs, 55% reached the HbA1c target after 2 years of weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching HbA1c target of 53 mmol/mol or lower, GLP-1RA-naive people
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Proportion HbA1c <=53 mmol/mol
55%
GLP-1RA-naive, 2 years
Source sentences
Summary
Similarly, 55% of GLP-1RA-naïve people and 43% of GLP-1RA-experienced people reached a HbA1c target of ≤53 mmol/mol after 2 years.
1 context sentence(design, population, supporting numbers)
Summary · context
People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included.
Report a problemFND-3680967803
04HumanObservational studyEfficacy outcome
In GLP-1RA-experienced people with type 2 diabetes, 43% reached an HbA1c target of 53 mmol/mol or lower after 2 years of once-weekly semaglutide.
In plain wordsIn people with type 2 diabetes who had used GLP-1 drugs before, 43% reached the HbA1c target after 2 years of weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching HbA1c target of 53 mmol/mol or lower, GLP-1RA-experienced people
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Proportion HbA1c <=53 mmol/mol
43%
GLP-1RA-experienced, 2 years
Source sentences
Summary
Similarly, 55% of GLP-1RA-naïve people and 43% of GLP-1RA-experienced people reached a HbA1c target of ≤53 mmol/mol after 2 years.
1 context sentence(design, population, supporting numbers)
Summary · context
People who redeemed at least one prescription of semaglutide and had 2 years of follow-up were included.
Report a problemFND-3680967804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT04261933

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)

Novo Nordisk A/Sn = 78913 Feb 2020 to 25 May 2021

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 28 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.